Drug Trial Radar · NCT05185011
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
Last checked: Nov 20, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 16, 2021
Primary completion
Feb 6, 2022
Study completion Feb 6, 2022
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
Conditions
- Erectile Dysfunction
- Pulmonary Arterial Hypertension
Interventions
TPN171HDrug
10 mg TPN171H tablets,single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax)Time frame: 72 hours after dosing
- Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity(AUC0-∞)Time frame: 72 hours after dosing
- Area under the plasma concentration versus time curve from the last time of dosing to the last measurable concentration (AUC0-t)Time frame: 72 hours after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Jilin University
Changchun, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.